Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition
This cross-sectional study identifies the prevalence of patents on risk evaluation and mitigation strategies and their association with delaying generic competition.
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2024-03, Vol.331 (11), p.976-978 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | This cross-sectional study identifies the prevalence of patents on risk evaluation and mitigation strategies and their association with delaying generic competition. |
|---|---|
| ISSN: | 0098-7484 1538-3598 1538-3598 |
| DOI: | 10.1001/jama.2024.0924 |